Trial Profile
International Multicenter Phase I Trial of Hydroxyurea in Combination With Dose-Intense Temozolomide in Recurrent Glioblastoma
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- Acronyms HUTMZ
- 28 Aug 2019 Planned End Date changed from 1 Jun 2020 to 1 Jun 2022.
- 28 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2021.
- 15 Mar 2018 New trial record